Medaxone (Ceftriaxone)

Ceftriaxone is a broad‑spectrum third‑generation cephalosporin used to treat infections caused by susceptible bacteria.

• Pneumonia: achieves clinical cure of community‑acquired and hospital‑acquired pneumonia.
• Meningitis: provides rapid bacterial eradication and reduces mortality in bacterial meningitis.
• Gonorrhea: eliminates Neisseria gonorrhoeae infection and prevents complications.
• Urinary tract infection: resolves infection and alleviates symptoms in uncomplicated and complicated UTIs.
• Skin and soft‑tissue infection: clears infection and promotes healing in cellulitis and wound infections.

• Ceftriaxone binds to penicillin‑binding proteins on the bacterial cell wall, inhibiting the final transpeptidation step of peptidoglycan synthesis. This disruption weakens the cell wall, leading to osmotic instability, cell lysis, and bacterial death. The drug exhibits time‑dependent killing against a wide spectrum of Gram‑positive and Gram‑negative organisms.

Ceftriaxone may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects

• Injection site pain: discomfort at the site of intramuscular or intravenous administration.
• Diarrhea: mild to moderate loose stools.
• Rash: erythematous skin eruption.
• Nausea: feeling of queasiness.
• Vomiting: expulsion of stomach contents.
• Elevated liver enzymes: transient increase in hepatic transaminases.

Serious or Rare Side Effects

• Anaphylaxis: severe, potentially life‑threatening allergic reaction.
• Clostridioides difficile‑associated colitis: severe diarrhea due to bacterial overgrowth.
• Stevens‑Johnson syndrome/toxic epidermal necrolysis: extensive skin detachment.
• Hemolytic anemia: destruction of red blood cells.
• Thrombophlebitis: inflammation of veins at the injection site.
• Calcium precipitation: risk of insoluble complexes when mixed with calcium‑containing solutions.

Ceftriaxone requires careful consideration of patient‑specific factors before use.

• Renal impairment: monitor renal function and adjust therapy as needed.
• Hepatic dysfunction: observe liver enzymes during prolonged treatment.
• Neonates (≤28 days) and infants (≤3 months) with hyperbilirubinemia: avoid due to risk of bilirubin displacement.
• Pregnancy and breastfeeding: use only if clearly indicated after risk‑benefit assessment.
• Known β‑lactam allergy: contraindicated in patients with hypersensitivity to cephalosporins or penicillins.
• Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze.

Ceftriaxone can interact with several medicines, affecting safety or efficacy.

Major Interactions (Avoid)

• Calcium‑containing IV solutions: may precipitate insoluble calcium‑ceftriaxone complexes.
• Warfarin: can enhance anticoagulant effect, increasing bleeding risk.
• Aminoglycosides: combined use may increase nephrotoxicity.
• Live vaccines: may reduce vaccine efficacy.
• Diuretics (e.g., furosemide): can exacerbate calcium precipitation risk.

Moderate Interactions (Monitor Closely)

• Oral contraceptives: possible reduction in contraceptive effectiveness.
• Probenecid: may increase ceftriaxone plasma concentrations.
• Other nephrotoxic agents (e.g., vancomycin): monitor renal function.
• Antacids containing aluminum or magnesium: may affect absorption if given orally (rarely applicable).